Identification of Potential Gene Markers and Insights into the Pathophysiology of Pheochromocytoma Malignancy

Archive ouverte

Thouennon, Erwan | Elkahloun, Abdel, G. | Guillemot, Johann | Gimenez-Roqueplo, Anne-Paule | Bertherat, Jérôme | Pierre, Alice | Ghzili, Hafida | Grumolato, Luca | Muresan, Mihaela | Klein, Marc | Lefebvre, Hervé | Ouafik, L’houcine | Vaudry, Hubert | Plouin, Pierre-Francois | Yon, Laurent | Anouar, Youssef

Edité par CCSD ; Endocrine Society -

International audience. Context: Pheochromocytomas are catecholamine-producing tumors that are generally benign but that can also present as or develop into malignancy. Occurrence of malignant pheochromocytomas can only be asserted by imaging of metastatic lesions. Objectives: We conducted a gene expression profiling of benign and malignant tumors to identify a gene signature that would allow us to discriminate benign from malignant pheochromocytomas and to gain a better understanding of tumorigenic pathways associated with malignancy. Design: A total of 36 patients with pheochromocytoma was studied retrospectively. There were 18 (nine benign and nine malignant) tumors used for gene expression profiling on pangenomic oligonucleotide microarrays. Results: We identified and validated a set of predictor genes that could accurately distinguish the two tumor subtypes through unsu-pervised clustering. Most of the differentially expressed genes were down-regulated in malignant tumors, and several of these genes encoded neuroendocrine factors involved in prominent characteristics of chromaffin cell biology. In particular, the expression of two key processing enzymes of trophic peptides, peptidylglycine-amidating monooxygenase and glutaminyl-peptide cyclotransferase, was reduced in malignant pheochromocytomas. Conclusion: The gene expression profiling of benign and malignant pheochromocytomas clearly identified a set of genes that could be used as a prognostic multi-marker and revealed that the expression of several genes encoding neuroendocrine proteins was reduced in malignant compared with benign tumors. (J Clin Endocrinol Metab 92: 4865– 4872, 2007)

Suggestions

Du même auteur

Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma

Archive ouverte | Guillemot, Johann | CCSD

International audience. We have previously demonstrated that measurement of tissue concentration of the novel secretogranin II-derived peptide EM66 may help to discriminate between benign and malignant pheo-chromocy...

Characterization and Plasma Measurement of the WE-14 Peptide in Patients with Pheochromocytoma

Archive ouverte | Guillemot, Johann | CCSD

International audience. Granins and their derived peptides are valuable circulating biological markers of neuroendocrine tumors. The aim of the present study was to investigate the tumoral chromogranin A (CgA)-deriv...

Expression and processing of the neuroendocrine protein secretogranin II in benign and malignant pheochromocytomas.

Archive ouverte | Guillemot, Johann | CCSD

International audience. The aim of the present study was to compare the expression levels of secretogranin II (SgII), prohormone convertases (PC)1 and PC2, and the proteolytic processing of SgII in benign versus mal...

Chargement des enrichissements...